EU-GMP Presence SOMAÍ operates as a leading EU-GMP European vertically integrated MCO with a robust cannabinoid pharmaceutical portfolio and a state-of-the-art Lisbon facility, presenting opportunities for pharmaceutical-grade supply, contract manufacturing, and compliant distribution within the EU.

Global Expansion With global sales teams and ongoing acquisitions and partnerships (e.g., Releaf, Sherbinskis, Canymed), SOMAÍ is expanding its footprint and channel reach, creating cross-border sales opportunities across Europe and into international markets through distribution, licensing, and co-branding deals.

Product Pipeline The company is building a robust pipeline of cannabis-based therapeutics and recently launching EU-GMP full-spectrum Essentials line extracts, offering sales opportunities for formulated pharmaceutical products, single-strain extracts, and comparable formulation partnerships.

Strategic Partnerships Recent and upcoming partnerships with clinics, dispensaries, wholesalers, and pharmaceutical distributors (e.g., Canymed, Releaf, Sherbinskis) signal strong routes to market and collaborative distribution channels to accelerate product uptake in multiple markets.

Growth Readiness Funding and revenue indicators position SOMAÍ for scale as they target further acquisitions and brand partnerships; aligned sales opportunities include contract manufacturing, private-label programs, and multi-market distribution deals to support rapid growth.